Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Navicare Biotech Co FCF Yield % Related Terms
Navicare Biotech Co FCF Yield % Historical Data
* Premium members only.
The historical data trend for Navicare Biotech Co's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8472 vs AMZN, BABA, PDD: FCF Yield % Comparison
For the Internet Retail subindustry, Navicare Biotech Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navicare Biotech Co FCF Yield % vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Navicare Biotech Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Navicare Biotech Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navicare Biotech Co (ROCO:8472) has a FCF Yield % of -0.23 as of Jul. 16, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Navicare Biotech Co and its competitors. According to the industry distribution chart, Navicare Biotech Co ranks #770 out of 1125 companies in the Retail - Cyclical industry, placing it in the top 68.4%.
Is Navicare Biotech Co's FCF Yield % too high?
Navicare Biotech Co's current FCF Yield % is -0.23. Based on the distribution chart, Navicare Biotech Co ranks #770 out of 1125 companies in the Retail - Cyclical industry, which is below the industry midpoint. Overall, Navicare Biotech Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Navicare Biotech Co's FCF Yield % compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Navicare Biotech Co ranks #770 out of 1125 companies for FCF Yield %. This places Navicare Biotech Co in the lower half of its industry. The industry median FCF Yield % is 4.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Retail - Cyclical company?
The median FCF Yield % among Retail - Cyclical companies is 4.32, based on 1,125 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Navicare Biotech Co and its competitors. For the Retail - Cyclical industry, the median FCF Yield % is 4.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navicare Biotech Co's current FCF Yield % is -0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navicare Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Navicare Biotech Co (ROCO:8472) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$44.21, compared to a current price of NT$79.00 — trading 78.7% above its estimated fair value. The current FCF Yield % is -0.23. Navicare Biotech Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Navicare Biotech Co (ROCO:8472), the current FCF Yield % is -0.23 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Navicare Biotech Co (ROCO:8472) Overvalued in 2026?
Based on GuruFocus' analysis, Navicare Biotech Co stock appears to be overvalued.
The current stock price of NT$79.00 is trading 78.7% above its estimated GF Value™ of NT$44.21.
GuruFocus considers Navicare Biotech Co to be Significantly Overvalued.
Key valuation signals for ROCO:8472:
FCF Yield %: -0.23
GF Value™: NT$44.21 vs. price of NT$79.00 (78.7% above fair value)
No single metric tells the full story. See the ROCO:8472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8472 has been successfully added to your 
